Australia markets open in 5 hours 5 minutes

Magenta Therapeutics, Inc. (MGTA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.73-0.14 (-2.04%)
At close: 4:00PM EDT
6.73 0.00 (0.00%)
After hours: 04:33PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.87
Open7.02
Bid6.56 x 2200
Ask7.26 x 1400
Day's range6.71 - 7.02
52-week range5.89 - 14.20
Volume105,652
Avg. volume241,389
Market cap394.158M
Beta (5Y monthly)2.15
PE ratio (TTM)N/A
EPS (TTM)-1.41
Earnings date03 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.71
  • Business Wire

    Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer

    CAMBRIDGE, Mass., October 04, 2021--Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced the appointment of Jeffrey Humphrey, M.D., as the company’s Chief Medical Officer where he will be responsible for all clinical development and regulatory initiatives.

  • Business Wire

    Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference

    CAMBRIDGE, Mass., September 21, 2021--Magenta Therapeutics, Inc. (Nasdaq:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28 at 4:40 p.m. ET.

  • Business Wire

    Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial

    CAMBRIDGE, Mass., September 15, 2021--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced today that its Investigational New Drug (IND) application for MGTA-117 is active with the U.S. Food and Drug Administration (FDA). The company expects to open the Phase 1/2 clinical trial in Q4 2021 to evaluate its MGTA-117 antibody-drug conjugate (ADC) targeted conditioni